Going Viral: Alzheimer’s Research at Herpes Conference Herpesvirus: Trigger for Many Brain Pathologies? In light of recent work implicating human herpesviruses in AD, virologists invited Alzheimer’s researchers to join them at the 11th International ...
Research presented at SfN strengthens the case that microglia gorge on synapses in some neurodegenerative and neurodevelopmental disorders.
Joint Keystone Symposia: Neurodegenerative Diseases: New Insights and Therapeutic Opportunities and Neural Environment in Disease: Glial Responses and Neuroinflammation
TREM2, Microglia Dampen Dangerous Liaisons Between Aβ and Tau Down to Sex? Boy and Girl Microglia Respond Differently Dopaminergic Neurons Conjured from Astrocytes Restore Motion In PD Model, α-Synuclein Spreads from Intestine to Brain Do Microglia Finish ...
A U.K. research program developed guidelines for clinical practice. In preliminary studies, it boosted diagnosis and improved patient care.
New Tool Kit Helps Physicians Recognize and Manage Lewy Body Dementias Consortia Assemble Worldwide to Take on Lewy Body Dementia Dementia with Lewy bodies is a devastating disorder, combining some of the worst features of Alzheimer’s and Parkinson’s, but ...
The field is searching for a combination of clinical features and biomarkers that will identify the disease in people with mild cognitive impairment.
The field is rapidly building the infrastructure for biomarker studies and large clinical trials.
Recruitment, recruitment, recruitment: Registries get creative in how they promote research engagement and fill prevention trials.
Middle-aged people who exercise more are less likely to become amyloid-positive. In late life, people with brain amyloid who exercise declined more slowly and had less brain shrinkage over the following years.
RPS25 helps translate repetitive snippets of RNA that are associated with neurodegenerative diseases. Knocking it down reduces protein aggregates and cell death.
Too much or too little serum hemoglobin increases risk for Alzheimer’s and other dementias by 20 percent or more.
The DIAN Trials Unit is nearing the end of its first two secondary prevention trials. It has begun a cognitive run-in period for its next trial, of a tau-based drug, and for a primary prevention study in people as young as 18.
As the Alzheimer’s field suffers smackdowns in trials of small molecules and antibodies, antisense oligonucleotides are quietly coming along—and looking safe so far.
A brother’s survival guilt, a journalist tracing her mutation to Lebanon, a student freezing her eggs ahead of a primary prevention trial—DIAN family members are stirring their growing community to act against Alzheimer’s disease.
At AD/PD Conference, New Alzheimer’s Genes Reinforce Known Pathways Expression, Expression, Expression—Time to Get on Board with eQTLs APP Upp: Mutation Nixes Six Amino Acids from Aβ, Spurs Aggregation Parsing How Alzheimer’s Genetic Risk Works Through ...